{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "apixaban",
    "comparative_drug": "dalteparin",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "non-inferiority, time-to-event analysis",
    "aim_of_study": "To assess the non-inferiority of oral apixaban compared to subcutaneous dalteparin for the treatment of newly diagnosed proximal DVT and/or PE in patients with cancer.",
    "target_disease": "newly diagnosed proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients with cancer",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "Non-inferiority of apixaban compared to dalteparin for the treatment of newly diagnosed proximal DVT and/or PE in cancer patients, based on time-to-event analysis.",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}